|
Abdominoplasty/Apronectomy (following significant weight loss) Referral proforma PP45 (Word, 92Kb)
|
|
Abdominoplasty/Apronectomy following Significant Weight Loss, Policy Position Statement (PP45), March 2025 (PDF, 145Kb)
|
|
Adult Congenital Heart Disease Services (Levels 1 and 2) for people aged 16 and over, Service Specification (CP214). June 2022 (PDF, 423Kb)
|
|
Adult Neurosurgery, Service Specification, (CP178), March 2023 (PDF, 731Kb)
|
|
Adult Thoracic Surgery, Service Specification (CP144), September 2020 (PDF, 450Kb)
|
|
Allogeneic Haematopoietic Stem Cell Transplant (HSCT) for people of all ages with Sickle Cell Disease (SCD), Commissioning Policy (CP224). November 2021 (PDF, 443Kb)
|
|
Alternative and Augmentative Communication (AAC), Commissioning Policy (CP93), May 2019 (PDF, 371Kb)
|
|
Asfotase alfa for treating paediatric-onset hypophosphatasia in children aged under 16 years, Policy Position Statement (PP156), November 2023 (PDF, 263Kb)
|
|
Ataluren for Treating Duchenne Muscular Dystrophy with a Nonsense Mutation in the Dystrophin Gene Policy Position Statement (PP118), July 2023 (PDF, 217Kb)
|
|
Atidarsagene Autotemcel for Treating Metachromatic Leukodystrophy in Children, Policy Position Statement, (PP257), April 2023 (PDF, 180Kb)
|
|
Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension (all ages), (PP162) March 2025 (PDF, 236Kb)
|
|
Berotralstat for preventing recurrent attacks of hereditary angioedema for people aged 12 years and older, Policy Position Statement (PP236). June 2022 (PDF, 277Kb)
|
|
Bevacizumab for the treatment of vestibular schwannomas in Neurofibromatosis Type 2 (now known as NF2-related vestibular schwannomatosis) (all ages) (CP254), August 2023 (PDF, 440Kb)
|
|
Bleeding Disorders (All Ages), Service Specification (CP77), June 2022 (PDF, 343Kb)
|
|
Body Contouring, Commissioning Policy (CP44). March 2025 (PDF, 293Kb)
|
|
Brachytherapy for the treatment of gynaecological malignancies for people aged 18 years and above, Commissioning Policy (CP75), July 2024 (PDF, 440Kb)
|
|
Brachytherapy in the Treatment of Localised Prostate Cancer, Commissioning Policy (CP01). September 2022 (PDF, 368Kb)
|
|
Breast Surgery Procedures, Commissioning Policy (CP69). March 2025 (PDF, 251Kb)
|
|
Burosumab for Treating X-linked Hypophosphataemia in Children and Young People, Policy Position (PP177), May 2019.pdf (PDF, 557Kb)
|
|
Canakinumab for treating periodic fever syndromes: TRAPS, HIDS/MKD and FMF (ages 2 and older), Policy Position Statement, (PP228). January 2022. (PDF, 324Kb)
|
|
Cannabidiol for treating seizures caused by tuberous sclerosis complex in people aged 2 years and above (PP272) December 2026 (PDF, 249Kb)
|
|
Cannabidiol with clobazam for treating seizures associated with Dravet syndrome or Lennox-Gastaut syndrome in people aged 2 years and older, Policy Position Statement (PP203), July 2024 (PDF, 388Kb)
|
|
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 for children aged under 16 years, Policy Position Statement (PP262), November 2023 (PDF, 233Kb)
|
|
Chimeric Antigen Receptor T Cell (CAR T) Therapy, Gilead Axicabtagene Ciloleucel (Yescarta®) Service Specification (CP175), March 2019 (PDF, 514Kb)
|
|
Chimeric Antigen Receptor T Cell (CAR T) Therapy, Novartis Tisagenlecleucel (Kymriah ®) Service Specification. (CP176), March 2019 (PDF, 571Kb)
|
|
Chimeric Antigen Receptor T Cell (CAR T) Therapy, Policy Position Statement, (PP185). April 2023 (PDF, 254Kb)
|
|
Circumcision for Children Aged up to 16 Years, Commissioning Policy (CP34). July 2024 (PDF, 507Kb)
|
|
Cleft Lip and/or Palate including Non-Cleft Velopharyngael Dysfuncion: All Ages, Service Specification (CP186), November 2025 (PDF, 591Kb)
|
|
Complex Devices Implantable Cardioverter Defibrillators and Cardiac Resynchronisation Therapy for arrhythmias and heart failure (PP151).pdf March 2025 (PDF, 234Kb)
|
|
Corneal cross-linking for keratoconus in children (from birth until their 16th birthday) commissioning policy, (CP271), October 2023 (PDF, 328Kb)
|
|
Cystic Fibrosis Modulator therapies Policy Position Statement, (PP198). March 2022 (PDF, 354Kb)
|
|
Cystic Fibrosis: Adults and Young People (CP193) Review Date Ext 2025 (PDF, 544Kb)
|
|
Deep Brain Stimulation, Commissioning Policy (CP28), July 2024 (PDF, 384Kb)
|
|
Dexrazoxane for Preventing Cardiotoxicity in Children (Aged Under 16 Years Old) Receiving High-Dose Anthracyclines or Related Drugs for the Treatment of Cancer, Policy Position Statement (PP253), February 2023 (PDF, 265Kb)
|
|
Dialysis Away from Base (DAFB) (Holiday Dialysis) (CP33) December 2024 (Word, 205Kb)
|
|
Drug Treatment for Lysosomal Storage Disorders (All Ages), Commissioning Policy (CP55), October 2024 (PDF, 696Kb)
|
|
Eating Disorder Outreach Service (EDOS) (for people aged under 18 years) Service Specification (SS295), August 2024 (PDF, 560Kb)
|
|
Eating Disorder Specialised Services Tier 4, Commissioning Policy (CP20). November 2011 (PDF, 320Kb)
|
|
Eculizimab for Atypical Haemolytic Uraemic Syndrome (aHUS), (CP98), November 2025 (PDF, 284Kb)
|
|
Eculizmab for Paroxysmal Nocturnal Haemoglobinuria (PNH), Commissioning Policy, (CP152), July 2024 (PDF, 779Kb)
|
|
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency (PP281) February 2027 (PDF, 212Kb)
|
|
Electrophysiology and Ablation Services (16 years and older), Commissioning policy (CP197a). January 2025 (PDF, 347Kb)
|
|
Electrophysiology and Ablation Services (16 years and older), Service Specification (CP197b) January 2025 (PDF, 331Kb)
|
|
Emicizumab as prophylaxis in people with congenital haemophilia A with Factor VIII inhibitors (all ages), Policy Position Statement (PP167). November 2018 (PDF, 316Kb)
|
|
Emicizumab as prophylaxis in people with severe congenital haemophilia A without factor VIII inhibitors, Policy Position Statement, (PP189), November 2023 (PDF, 288Kb)
|
|
Everolimus for refractory focal onset seizures associated with tuberous sclerosis complex (aged 2 years and above) (PP250) December 2026 (PDF, 258Kb)
|
|
Everolimus for renal angiomyolipoma associated with tuberous sclerosis complex (TSC) in adults (PP274) December 2026 (PDF, 332Kb)
|
|
Everolimus for subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) (all ages) (PP273) December 2026 (PDF, 335Kb)
|
|
Everolimus for the prevention of organ rejection following heart transplantation, Policy Position Statement (PP103), July 2019 (PDF, 164Kb)
|
|
Extra corporeal membrane oxygenation (ECMO) service for adults with cardiac failure, Policy Position Statement, (PP102). July 2019 (PDF, 141Kb)
|
|
Extracorporeal Membrane Oxygenation (ECMO) as a Bridge to Lung Transplant (BTLT) (All Ages), Policy Position Statement, (PP251), February 2023 (PDF, 288Kb)
|
|
Facial Surgery procedures, Commissioning Policy (CP43). March 2025 (PDF, 325Kb)
|
|
Facial Surgery procedures: Referral proforma Blepharoplasty (CP43) (Word, 92Kb)
|
|
Facial Surgery procedures: Referral proforma Face lift/brow lift (CP43) (Word, 92Kb)
|
|
Facial Surgery procedures: Referral proforma Miscellaneous (CP43) (Word, 91Kb)
|
|
Facial Surgery procedures: Referral proforma Pinnaplasty (CP43) (Word, 91Kb)
|
|
Facial Surgery procedures: Referral proforma Rhinoplasty (CP43) (Word, 92Kb)
|
|
Gatekeeping, Placement and Case Management for Specialised Mental Health Services, CP232, June 2022 (PDF, 399Kb)
|
|
Gender Identity Service for Adults (non-surgical) Commissioning Policy (CP182) Review Ext January 2025 (PDF, 680Kb)
|
|
Gender Identity Service for Adults (non surgical) Service Specification (CP182b) July 2024 (PDF, 741Kb)
|
|
Genomics Service Specification (CP99). June 2022 (PDF, 572Kb)
|
|
Genomic Testing, Policy Position Statement, (PP184). June 2020 (PDF, 231Kb)
|
|
Givosiran for Treating Acute Hepatic Porphyria for People Aged 12 Years and Older, (PP252), Policy Position Statement, April 2023 (PDF, 131Kb)
|
|
Haematopoietic stem cell transplantation for adults, Service Specification (CP79). January 2020 (PDF, 295Kb)
|
|
Haematopoietic stem cell transplantation, Policy Position Statement, (PP142). January 2020 (PDF, 553Kb)
|
|
Hepatobiliary Surgery, Service Specification (CP73). November 2021 (PDF, 344Kb)
|
|
Hyperbaric Oxygen Therapy, Commissioning Policy (CP07), July 2023 (PDF, 363Kb)
|
|
Inherited White Matter Disorders Policy Position Statement (PP239) May 2023 (PDF, 565Kb)
|
|
In-patient Child and Adolescent Mental Health Services (CAMHS): General Adolescent (GAU) and Extra Care Area (ECA), Service Specification (CP150), November 2026 (PDF, 547Kb)
|
|
Living Donor Expenses, Commissioning Policy (CP30), December 2026 (PDF, 307Kb)
|
|
Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (NETs), Policy Position Statement (PP195), November 2026 (PDF, 334Kb)
|
|
Lymphovenous Anastamosis (LVA) microsurgery for Primary and Secondary Lymphoedema, Commissioning Policy (CP87b). August 2015 (PDF, 501Kb)
|
|
Lymphovenous Anastamosis (LVA) microsurgery for Primary and Secondary Lymphoedema, Service Specification (CP87a). August 2015 (PDF, 380Kb)
|
|
Major Trauma Centre, Appendix 1, Commissioning & governance arrangements for partner organisations within the Major Trauma Network. (CP188) February 2021 (PDF, 345Kb)
|
|
Major Trauma Centre, Appendix 2: Quality Indicators. (CP188) February 2021 (PDF, 665Kb)
|
|
Major Trauma Centre, Service Specification (CP188), February 2021 (PDF, 403Kb)
|
|
Mechanical Thrombectomy for the treatment of acute Ischaemic Stroke, Commissioning Policy (CP168). March 2025 (PDF, 887Kb)
|
|
Microprocessor controlled prosthetic knees, Commissioning Policy (CP218). December 2021 (PDF, 388Kb)
|
|
National Acute Porphyria, Service Specification (CP166). February 2025 (PDF, 274Kb)
|
|
Neonatal Services (Intensive Care, High Dependency and Special Care) (CP263) August 2024 (PDF, 481Kb)
|
|
Neonatal Services (Intensive Care, High Dependency and Special Care) (SS263) August 2024 (PDF, 591Kb)
|
|
Neuropsychiatric Rehabilitation (Specialised), Commissioning Policy, (CP128), August 2024 (PDF, 327Kb)
|
|
New Treatment Fund (CP159) January 2025 (PDF, 354Kb)
|
|
NHS Wales Specialist Children and Young People Gender Identity Services (PDF, 1.7Mb)
|
|
Nusinersen for treating spinal muscular atrophy, Policy Position Statement (PP191), November 2026 (PDF, 400Kb)
|
|
Obesity Surgery for Complex and Severe Obesity Level 4 (Adults), Commissioning Policy, (CP29a), March 2023 (PDF, 316Kb)
|
|
Obesity Surgery for Complex and Severe Obesity- Level 4 (Adults), Service Specification (CP29b), March 2023 (PDF, 383Kb)
|
|
Odevixibat for Treating Progressive Familial Intrahepatic Cholestasis, Policy Position Statement, (PP249), February 2023 (PDF, 193Kb)
|
|
Paediatric Endocrinology, Service Specification (SS163), June 2024 (PDF, 512Kb)
|
|
Paediatric Epilepsy, Commissioning Policy (CP174), September 2022 (PDF, 487Kb)
|
|
Paediatric Nephrology Service Specification, CP169 (March 2021) (PDF, 443Kb)
|
|
Pasireotide for Cushing's Disease, Policy Position (PP155), July 2019 (PDF, 252Kb)
|
|
Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors (NET) in Adults, Service Specification, (CP266), March 2023 (PDF, 300Kb)
|
|
Percutaneous Mitral Valve Leaflet repair for primary degenerative mitral regurgitation in adults, Policy Position Statement (PPS206), June 2021 (PDF, 572Kb)
|
|
Perinatal post-mortem investigation of fetal and neonatal deaths (England, Scotland and Wales). Interim Clinical Commissioning Urgent Policy Statement. October 2022 (PDF, 304Kb)
|
|
Personalised External Aortic Root Support (PEARS) for surgical management of enlarged aortic root (adults), Policy Position Statement, (PP104). March 2025 (PDF, 195Kb)
|
|
Pipeline Embolisation Devices used for the treatment of Intracranial Aneurysms (Complex Giant or Large Intracranial Aneurysms), Commissioning Policy (CP101). July 2015 (PDF, 352Kb)
|
|
Plerixafor for Stem Cell Mobilisation, Policy Position Statement (PPS154) Review Date Ext January 2025 (PDF, 499Kb)
|
|
Positron Emission Tomography (PET) (CP50), Commissioning Policy, April 2024 (PDF, 488Kb)
|
|
Positron Emission Tomography (PET), Service Specification (CP50b). September 2020 (PDF, 514Kb)
|
|
Posture and Mobility Services for Children, Young People and Adults, Commissioning Policy (CP59), June 2024 (PDF, 472Kb)
|
|
Posture and Mobility Services for Children, Young People and Adults, Service Specification (SS59), June 2024 (PDF, 496Kb)
|
|
Preimplantation Genetic Diagnosis (PGD), Commissioning Policy (CP37). March 2025 (PDF, 445Kb)
|
|
Prosthetic Provision, Service Specification (CP89). March 2025 (PDF, 433Kb)
|
|
Proton Beam Therapy for adults with cancer Commissioning Policy (CP147), July 2023 (PDF, 279Kb)
|
|
Proton Beam Therapy for children, teenagers and young adults (TYA) with cancer, Commissioning Policy (CP148), April 2023 (PDF, 231Kb)
|
|
Recreational and Sport Prosthetics for a Child or Young Adult up to the age of 25, Commissioning Policy (CP221). November 2021 (PDF, 402Kb)
|
|
Revision Surgery for Severe and Complex Obesity (Adults), Commissioning Policy, (CP259), May 2023 (PDF, 273Kb)
|
|
RFA for Barretts Oesophagus Service v1.0 (CP183) Review Date Ext March 2025 (PDF, 481Kb)
|
|
Risdiplam for Spinal Muscular Atrophy for people aged under 16 years, Policy Position Statement (PP240). May 2022 (PDF, 361Kb)
|
|
Rituximab and Eculizumab for the Prevention and Management of Delayed Haemolytic Transfusion Reactions and Hyperhaemolysis in people with Hereditary Anaemias, Policy Position Statement (PP237), February 2023 (PDF, 438Kb)
|
|
Salvage Cryotherapy for Prostate Cancer, Policy Position Statement, (PP173). June 2020 (PDF, 188Kb)
|
|
Sapropterin for treating hyperphenylalaninaemia (HPA) in phenylketonuria (PKU) and tetrahydrobiopterin (BH4) disorders, Policy Position (PP223), January 2023 (PDF, 464Kb)
|
|
Selective Dorsal Rhizotomy (SDR) for the treatment of spasticity in cerebral palsy in children aged 3-9 years, Policy Position Statement (PP245), March 2024 (PDF, 975Kb)
|
|
Selective internal radiation therapies (SIRT) for treating adults with hepatocellular carcinoma, Policy Position Statement, (PP227). November 2021 (PDF, 303Kb)
|
|
Selexipag for the Treatment of Pulmonary Arterial Hypertension (Adults), Policy Position (PP105), March 2019.pdf (PDF, 255Kb)
|
|
Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over, Policy Position Statement (PP267), September 2023 (PDF, 228Kb)
|
|
Services for Children with Cancer, (CP86), December 2024 (PDF, 545Kb)
|
|
Sickle Cell Disorders, Thalassaemia Disorders and other Rare Hereditary Anaemias, Service Specification (CP179). December 2020 (PDF, 494Kb)
|
|
Soft Tissue Sarcoma, Service Specification (CP149), June 2020 (PDF, 396Kb)
|
|
Specialised Fetal Medicine, Commissioning Policy, (CP97), October 2023 (PDF, 372Kb)
|
|
Specialised Immunology, Service Specification (SS78), October 2024 (PDF, 615Kb)
|
|
Specialised Paediatric Gastroenterology, Hepatology and Nutrition (PGHAN) Service Specification (CP211) May 2023 (PDF, 759Kb)
|
|
Specialised Paediatric Neurological Rehabilitation, Commissioning Policy (CP160), November 2024 (PDF, 385Kb)
|
|
Specialised Paediatric Neurology, Service Specification (SS213), June 2024 (PDF, 492Kb)
|
|
Specialised Paediatric Rheumatology Service Specification (CP172). November 2021 (PDF, 475Kb)
|
|
Specialised Services Policy: Extracorporeal Photophoresis (ECP) for the Treatment of Chronic Graft versus Host Disease in Adults (CP91), November 2015 (PDF, 658Kb)
|
|
Specialised Services Policy: Extracorporeal Photophoresis (ECP) for the Treatment of Cutaneous T-cell Lymphoma (CP92), November 2015 (PDF, 624Kb)
|
|
Specialist Fertility Services, Commissioning Policy (CP38), April 2025 (PDF, 360Kb)
|
|
Specialist Perinatal Mental Health Inpatient Service (Mother and Baby Unit) CP201, Service Specification. April 2021 (PDF, 474Kb)
|
|
Specialist Spinal Cord Injury Rehabilitation, Commissioning Policy (CP141). February 2025 (PDF, 438Kb)
|
|
Specialist Neurological Rehabilitation, Commissioning Policy (CP140), November 2024 (PDF, 433Kb)
|
|
Spinal Services Operational Delivery Network (CP241) June 2022 (PDF, 381Kb)
|
|
SRFA for Barretts Oesophagus Service v1.0 (SS183) Review Ext March 2025 (PDF, 496Kb)
|
|
Stereotactic ablative body radiotherapy (SABR) for patients aged 18 years old and above (PP278) August 2026 (PDF, 511Kb)
|
|
Stereotactic ablative body radiotherapy (SABR) for patients aged 18 years old and above with (LANPC) (PP280) August 2026 (PDF, 371Kb)
|
|
Stereotactic Ablative Body Radiotherapy (SABR) for the management of Non-Small Cell Lung Cancer in people aged 18 years and above, Commissioning Policy (CP76) June 2023 (PDF, 525Kb)
|
|
Stereotactic Ablative Body Radiotherapy (SABR) Service Specification (CP219) June 2021 (PDF, 356Kb)
|
|
Stereotactic ablative radiotherapy (SABR) for patients with hepatocellular carcinoma (HCC) (Adults), Commissioning Policy (CP124), December 2021 (PDF, 398Kb)
|
|
Stereotactic Ablative Radiotherapy (SABR) for people aged 18 years old and above with primary kidney cancer, Commissioning Policy (CP279), June 2024 (PDF, 512Kb)
|
|
Stereotactic Ablative Radiotherapy (SABR) in the treatment of Oligometastatic disease, Commissioning Policy (CP121). October 2021 (PDF, 387Kb)
|
|
Stereotactic Radiosurgery for Adults, Teenagers and Young Adults (TYA) (CP22) June 2026 (PDF, 455Kb)
|
|
Teduglutide for Treating Short Bowel Syndrome, Policy Position Statement, (PP265), May 2023 (PDF, 130Kb)
|
|
Tier 4 Forensic Child and Adolescent Mental Health Service (Forensic Adolescent Consultation Service – Consultation and Advice for Child and Adolescent Mental Health Services), Service Specification, (CP222), August 2023 (PDF, 523Kb)
|
|
Tofacitinib for treating juvenile idiopathic arthritis in people aged 2 to 16 years, Policy Position Statement (PP229). May 2022 (PDF, 311Kb)
|
|
Transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic stenosis (SSAS), Commissioning Policy (CP58), March 2019 (PDF, 295Kb)
|
|
Transcranial magnetic resonance guided focused ultrasound (TcMRgFUS) thalamotomy for treatment of medication-refractory essential tremor for people aged 18 and over, Policy Position Statement, (PP258), August 2023 (PDF, 298Kb)
|
|
Trauma Operational Delivery Network, Service Specification (CP199). February 2021 (PDF, 663Kb)
|
|
Traumatic Stress Wales, Service Specification (SS212), November 2020 (PDF, 607Kb)
|
|
Treatment of Benign Skin Conditions, Commissioning Policy (CP42). March 2025 (PDF, 291Kb)
|
|
Treatment of Benign Skin Conditions, Referral Proforma Resurfacing (CP42) (Word, 91Kb)
|
|
Treatment options for Transthyretin Amyloidosis in Adults, Policy Position Statement (PP187), September 2023 (PDF, 307Kb)
|
|
Vagus Nerve Stimulation for adults, young persons and children, Commissioning Policy (CP23), May 2024 (PDF, 446Kb)
|
|
Volanesorsen for treating familial chylomicronaemia syndrome, Policy Position Statement, (PP217). October 2021 (PDF, 285Kb)
|
|
Vonicog alfa for the treatment and prevention of bleeding in people of all ages with von Willebrand disease, Policy Position Statement (PP215) (PDF, 353Kb)
|
|
Voretigene Neparvovec for Treating Inherited Retinal Dystrophies Caused by RPE65 Gene Mutations (PP196), March 2020 (PDF, 277Kb)
|
|
War Veterans – Enhanced Prosthetic Provision, Commissioning Policy (CP40), October 2020 (PDF, 408Kb)
|
|
Welsh Artificial Eye Service (WAES) (All Ages), Service Specification (CP238), December 2022 (PDF, 453Kb)
|